UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/508,893	01/26/2005	Scott K. Thompson	P51330	9702
	7590 08/23/200 BEECHAM CORPOR	PRATION EXAMINER		IINER
		OPERTY-US, UW2220	OH, TAYLOR V	
P. O. BOX 153 KING OF PRU	9 ISSIA, PA 19406-0939	ART UNIT PAPER NUMBER		PAPER NUMBER
12.70 01 1110	, , , , , , , , , , , , , , , , , , , ,		1625	
			MAIL DATE	DELIVERY MODE
			08/23/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/508,893	THOMPSON ET AL.			
		Examiner	Art Unit			
		Taylor Victor Oh	1625			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	Responsive to communication(s) filed on 25 M	a <u>y 2007</u> .				
2a) <u></u> □	This action is FINAL . 2b) This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4) 🛛	4)⊠ Claim(s) <u>1-23,25-47 and 56-58</u> is/are pending in the application.					
-	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)□	6) Claim(s) is/are rejected.					
	Claim(s) is/are objected to.					
8) Claim(s) <u>1-23, 25-47, 56-58</u> are subject to restriction and/or election requirement.						
Applicati	on Papers					
9)	The specification is objected to by the Examine	r.				
10)	The drawing(s) filed on is/are: a) acce	epted or b) objected to by the	e Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachmen	t(s)					
	e of References Cited (PTO-892)	4)				
3) Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal 6) Other:				

Art Unit: 1625

The Lack of Unity

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-23 is drawn to the none-hetero containing various aliphatic and cyclic compounds following compound formula (I) as disclosed below

Group II, claims 1-21, and 23, is drawn to the hetero cyclic compound following compound formula (I) as disclosed below:

Art Unit: 1625

Group III, claims 25-47 is drawn to the method of the prevention or treatment of an LXR mediated disease by using non-hetero compound containing various aliphatic and cyclic compounds following compound formula (I) as disclosed below:

Group IV, claims 25-41, 43-47, is drawn to the method of the prevention or treatment of an LXR mediated disease by using hetero compounds containing various heterocylic compounds following compound formula (I) as disclosed below:

following compound formula (I) as disclosed below:

Application/Control Number: 10/508,893

Art Unit: 1625

I. The inventions listed as Groups do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (" requirement of unity of invention").

PCT Rule 13.2 states "Where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

In the instant case, the invention II is related to the side chain group of hetero cylic compounds of formula (I), whereas the invention I is related to the side chain non-hetero of the formula (I).

The heterocylic radical group in Group II has a chemical structure and atoms in the ring, different from the non-heteroaryl radical group in Group I since each will exhibit a chemically different activity respectively. Each invention has a different use and effect due to the unrelated substituent attached to the core of the compounds. Therefore, there is no special technical feature required in Group II. There is no single general inventive concept and no unity of invention for the method or the processes as defined in 37 CFR 1.475.

In the instant case, the invention of Group of the invention I is related to the side chain non-hetero compounds of the formula (I), whereas the invention IV is related to the method of the prevention or treatment of an LXR mediated disease by using hetero compounds containing various heterocylic compounds following compound formula (I); they are different to each other because Schulman et al (US 6,924,311) teaches the use of LXR selelctive agonist compounds different from the Group of the invention I. Therefore, they are unrelated to each other; Group IV is not directly related to the Group I.

Art Unit: 1625

37 CFR 1.475 states that a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combination of categories:

- a. A product and a process specially adapted for the manufacture of said product; or
- b. A product and a process of use of said product; or
- c. A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- d. A process and an apparatus or means specially designed for carrying out the said process; or
- e. A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specially designed for carrying out the said process.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1625

II. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taylor Victor Oh whose telephone number is 571-272-0689. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TAYLOR VICTOR OH PRIMARY EXAMINER

Var

8/20/09
